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Previous studies have provided conflicting evidence regarding the association of
the serotonin transporter (5-HTT) gene with autism. Two polymorphisms have been
identified in the human 5-HTT gene, a VNTR in intron 21 and a functional
deletion/insertion in the promoter region (5-HTTLPR) with short and long variants.2
Positive associations of the 5-HTTLPR polymorphism with autism have been
reported by two family-based studies, but one found preferential transmission of
the short allele3 and the other of the long allele.4 Two subsequent studies failed t o
find evidence of transmission disequilibrium at the 5-HTTLPR locus.5,6 These
conflicting results could be due to heterogeneity of clinical samples with regard t o
serotonin (5-HT) blood levels, which have been found to be elevated in some
autistic subjects.7-9 Thus, we examined the association of the 5-HTTLPR and VNTR
polymorphisms of the 5-HTT gene with autism, and we investigated the relationship
between 5-HTT variants and whole-blood 5-HT. The transmission/disequilibrium test
(TDT) revealed no linkage disequilibrium at either loci in a sample of 96 families
comprising 43 trios and 53 sib pairs. Furthermore, no significant relationship between
5-HT blood levels and 5-HTT gene polymorphisms was found. Our results suggest
that the 5-HTT gene is unlikely to play a major role as a susceptibility factor in
autism.
Family and twin studies indicate that autism is one of the most strongly genetic
neuropsychiatric disorders.10,11 The pattern of recurrence risk among relatives suggests that
several interacting genes are likely to underlie susceptibility to autism.11 Genetic factors
predisposing to autism may also confer a risk for a broader phenotype that extends beyond
strictly defined autism to include a range of related but milder behavioral deficits. Indeed,
cognitive, social, and language impairments are more frequently observed among relatives of
autistic probands than among relatives of controls.12 Similarly, elevated levels of whole blood
or platelet serotonin (5-hydroxytryptamine, 5-HT) have been consistently observed in about
one third of autistic subjects7 and in their first-degree relatives,8,9,13,14 suggesting that
hyperserotonemia may be a marker of genetic susceptibility to autism. Other lines of evidence
also suggest that a dysregulation in serotonergic neurotransmission might be involved in the
pathogenesis of autism. Short-term dietary depletion of the 5-HT precursor tryptophan results
in an exacerbation of behavioral symptoms in autistic subjects.15 Conversely, 5-HT reuptake
inhibitors, which block the reuptake of 5-HT into the presynaptic neuron by inhibiting the 5-HT
transporter (5-HTT), appear to be of some benefit in the treatment of autistic symptoms such
H
AL author m
anuscript    inserm
-00124375, version 1
C Betancur et al 3
as ritualistic behavior and aggression.16,17 These data suggest that the 5-HTT is a compelling
candidate gene for autism.
Two common polymorphisms of the 5-HTT gene have been described, a variable number
of tandem repeats (VNTR) in intron 2 (serotonin transporter intron 2, STin2),1 and a
deletion/insertion in the 5’-flanking regulatory region (5-HTT gene-linked polymorphic region, 5-
HTTLPR).2 The 5-HTTLPR polymorphism consists of varying lengths of a repetitive
sequence comprising 20-23-bp-long repeat elements; the deletion/insertion results in two
major alleles, long and short, corresponding to 14 and 16 copies of the repeat element. The
short variant reduces the transcriptional efficiency of the 5-HTT gene promoter, resulting in
decreased 5-HTT expression and lower 5-HT uptake activity.2,18,19
Two recent family-based studies suggested an association of the 5-HTTLPR
polymorphism with autism, but their findings were conflicting. Cook et al3 reported preferential
transmission of the short variant in a sample of families from the United States, whereas
Klauck et al4 observed preferential transmission of the long allele in a German sample. Neither
study found evidence for an association with the VNTR polymorphism. Two subsequent
family-based association studies failed to find linkage disequilibrium of either allele of the 5-
HTTLPR polymorphism with autism.5,6 Moreover, a case-control study also reported lack of
association of 5-HTTLPR variants with autistic disorder.20
These discrepant findings might be explained by heterogeneity in the patient populations
studied, particularly regarding 5-HT blood levels. Indeed, hyperserotonemia in autistic patients
appears to result from an increased rate (Vmax) of 5-HT uptake by platelets.21 Given that 5-
HTTLPR variants have been shown to affect the Vmax of 5-HT uptake in human blood
platelets,19 it would be interesting to evaluate the possible association between 5-HTT gene
polymorphisms and 5-HT blood levels in autistic subjects. Thus, the purpose of the present
study was to further investigate the association between 5-HTT gene polymorphisms and
autism in a sample of trios and sib pairs recruited by the Paris Autism Research International
Sibpair (PARIS) study, by using whole blood 5-HT levels as an endophenotype in addition
to clinical classification. Use of quantitative traits, such as concentrations of neurotransmitters,
in addition to dichotomous qualitative traits classically employed, could improve phenotypic
characterization and contribute to the identification of more genetically homogeneous
subgroups.
The results of the TDT analysis for the alleles of the 5-HTTLPR and intron 2 VNTR
polymorphisms are presented in Table 1. The TDT analysis in sib pair families was performed
by counting transmissions to both affected siblings. No preferential transmission of either short
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or long alleles of the 5-HTTLPR locus was detected when analyzing the samples of trios and
sib pairs separately or combined. Similarly, analysis of the intronic VNTR polymorphism
revealed no evidence for association in the total sample or in the subset of trios or sib-pair
families.
The haplotype analysis of the two markers in the total sample and in the sib-pair families
yielded non-significant results (Table 2). However, in the trio sample, TDT analysis of the
haplotypes revealed a significant transmission distortion (TDT χ2 = 6.42, df = 4, p<0.02). In
these families, the long/STin2.12 haplotype was less transmitted than expected by chance
(χ2 = 5.85, df = 1, p<0.02).
Linkage analysis in the affected sib pairs revealed no increased allele-sharing for either
locus. Two-point NPL scores for the 5-HTTLPR and intron 2 VNTR polymorphisms were 1.36
(p<0.09) and –0.24 (p<0.58), respectively. Multipoint analysis yielded similar, non-significant
results (maximum NPL score = 1.00, p = 0.14).
Table 3 shows 5-HTT genotypes for the promoter and the intronic VNTR polymorphisms
and whole blood 5-HT levels in autistic probands. Blood 5-HT concentration in 45 autistic
patients was 1.07 ± 0.69 µmol/l (mean ± SD). With hyperserotonemia defined as a 5-HT level
greater than 0.9 µmol/l, 55% (25/45) affected individuals were hyperserotonemic. ANOVA
revealed no significant effect of 5-HTTLPR or intron 2 VNTR genotypes on 5-HT levels
(F(2,44) = 2.29, p = 0.11; and F(3,43) = 1.11, p = 0.35, respectively). Blood 5-HT levels
were higher in patients homozygous for the long allele of the 5-HTTLPR polymorphism (1.48 ±
1.31 µmol/l) than in individuals with one or two copies of the short allele (0.96 ± 0.34 µmol/l),
although this difference was not significant (Student's t-test, separate variances, t = 1.25; p =
0.24).
Our results revealed no evidence of association between autistic disorder and 5-HTT
promoter variants in 43 trios and 53 sib-pair families. Similarly, two other TDT studies failed to
reveal an association of the 5-HTTLPR locus with autism in their data sets: Maestrini et al5
studied 82 multiplex families and 8 trios and Persico et al6 tested 86 trios and 5 multiplex
families. These negative findings are in contrast with the initial reports by Cook et al3 and
Klauck et al.4 Cook et al3 observed a preferential transmission of the short allele of the 5-
HTTLPR in a sample of 86 trios, whereas Klauck et al4 reported a preferential transmission of
the long allele in a sample of 65 trios. A meta-analysis of the 5-HTTLPR polymorphism in the
four family-based association studies published to date3-6 and our results, comprising 504
heterozygote parents, indicated no association of either allele with autistic disorder; the short
allele was transmitted 262 times versus 242 times not transmitted (χ2 = 0.79, df = 1, p = 0.37).
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Thus, it is possible that the conflicting findings concerning the 5-HTTLPR result from spurious
association to the 5-HTT gene, due to the relatively small patient samples tested by Cook et
al3 and Klauck et al.4 Alternatively, the contradictory data might be a consequence of the
genetic heterogeneity underlying autism, suggesting that the 5-HTT gene could be involved in
the susceptibility to autism only in a small subset of patients.
The 5-HTT VNTR in intron 2 has been found to be associated with affective disorders and
has recently been shown to act as a transcriptional regulator in an allele-dependent fashion,22
thus providing a potential mechanism for its contribution to disease susceptibility. In
agreement with previous studies,3-5 our results did not reveal an association between the
STin2 VNTR polymorphism and autism in the total sample of trios and sib-pair families.
However, in the subsample of trios, the long/STin2.12 haplotype was less transmitted to
autistic patients than what would be expected by chance. This finding is unlikely to represent
a true association, given that the linkage disequilibrium disappears when analyzing the trios
and sib-pairs together.
In the present study we also tested the association between the two 5-HTT gene
polymorphisms and blood 5-HT levels. Hyperserotonemia, observed in patients with autism
as well as in their first-degree relatives,8,9,13,14 is one of the potential endophenotypes that
could be used to identify more homogenous groups of subjects carrying a vulnerable
genotype, thereby facilitating the detection of genes involved in autism. Neither the 5-
HTTLPR nor the intron 2 VNTR polymorphism were associated with whole blood 5-HT
concentration. Given the limited sample size used to measure 5-HT levels, the lack of
significant findings do not completely dispel the potential relationship between blood 5-HT
levels and 5-HTT polymorphisms in autistic subjects and further studies in other populations
are required.
Although the mechanisms responsible for hyperserotonemia in autistic subjects remain
unclear, converging evidence suggests that high 5-HT levels result from increased platelet
uptake.14,21 In vitro functional studies have shown that the long allele of the 5-HTTLPR
polymorphism displays increased transcriptional activity, resulting in enhanced 5-HTT protein
expression and higher 5-HT uptake in transfection assays2 and human lymphoblasts.18
Furthermore, the long allele is associated with a more rapid 5-HT uptake (Vmax) in human blood
platelets.19 The short variant appears to exert a dominant influence, since 5-HTT expression
and uptake are indistinguishable in lymphoblasts and platelets from individuals homozygous
or heterozygous for the short allele.18-19 In agreement with the present results in autistic
probands, Greenberg et al19 reported that the 5-HTTLPR polymorphism did not influence
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platelet 5-HT levels in healthy male volunteers. Indeed, the only index of platelet 5-HTT
function affected by the 5-HTTLPR genotype was the Vmax of 5-HT uptake, thus supporting
a previous finding showing that the Vmax, but not the affinity (Km), is highly heritable.23
In conclusion, the present findings do not support the existence of association between the
5-HTTLPR or the VNTR polymorphism in intron 2 and autism in our set of families, suggesting
that genetic variability of the 5-HTT gene is not a major risk factor for autism. Furthermore, our
results do not support an association between 5-HTT gene polymorphisms and 5-HT blood
levels in autistic patients. In view of the heterogeneity of the genetic mechanisms underlying
complex psychiatric disorders such as autism, further studies of the 5-HTT gene in subgroups
of patients with particular phenotypic characteristics are indicated.
Materials and methods
Families
Trios were recruited at an outpatient university clinic in Paris (Hôpital Robert Debré). Families
with at least two children with autistic disorder were recruited by the PARIS study at
specialized clinical centers in seven countries (Austria, Belgium, France, Italy, Norway,
Sweden, and the United States). All patients fulfilled the DSM-IV criteria for autistic disorder
and the Autism Diagnostic Interview-Revised (ADI-R) algorithm for ICD-10 childhood autism.24
Subjects were included after a complete clinical and neuropsychological evaluation described
previously.25 Patients diagnosed with associated organic conditions or other established
chromosomal disorders were excluded. Informed consent was obtained from all families
participating in the study. The study was approved by the ethical committees of the
collaborating institutions.
Fifty-three families with at least two affected siblings (including one family with three autistic
children) and 43 trios were included in the study. All the sib-pairs were Caucasians; among
the trios, 40 were Caucasians, 2 Caucasian/African Caribbean, and 1 Caucasian/African. The
mean age of the probands was 14.5 years (age range, 4-44); 109 subjects were male and 41
were female.
Genotyping
DNA was prepared from peripheral blood leukocytes using standard procedures. The 5-
HTTLPR was amplified by polymerase chain reaction (PCR) using primers stpr5 (5'-
GGCGTTGCCGCTCTGAATGC-3') and stpr3 (5'-GAGGGACTGAGCTGGACAACCAC-
3'), which yielded short (484 bp) and long (528 bp) fragments. The PCR products were
separated by electrophoresis on 2% agarose gels and stained with ethidium bromide. The 5-
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HTT VNTR polymorphism in the second intron was amplified using primers hst1 (5'-
GCTGTGGACCTGGGCAATGT-3') and hst2 (5'-GACTGAGACTGAAAAGACATAATC-3').
These primers amplified three alleles, containing 9 (STin2.9), 10 (STin2.10) or 12 (STin2.12)
copies of the 17-bp repeat element. The PCR products were resolved by electrophoresis on
8% polyacrylamide gels and silver staining.
Whole blood 5-HT
Blood 5-HT levels were measured in 45 autistic probands recruited in Paris, belonging mostly
to singleton families (42/45). Blood was drawn between 9 and 11 a.m. after two days of a diet
low in tryptophan and 5-HT. Whole blood 5-HT content was measured using a
radioenzymatic assay.26 Because more than 99% of blood 5-HT is in the platelet fraction, this
assay is a reliable measure of platelet content of 5-HT.
Statistical analysis
Standard biallelic TDT,27 allele-wise TDT and genotype wise-TDT for multiallelic markers were
performed using the ETDT program.28 Haplotype frequencies were estimated using the
program TRANSMIT29 which performs estimation from the data by maximum likelihood.
Haplotype transmission was tested using the same program. When transmission or parental
haplotype assignments are uncertain, TRANSMIT averages observed transmission
frequency over all the possible assignments consistent with the observed data (thus resulting
in observations with decimal values). In addition to the global test of deviation of the random
transmission frequencies, TDT was carried out for each specific haplotype. Non parametric
linkage analysis was performed using the program GENEHUNTER (NPLall statistic).30
Multipoint NPL scores were computed assuming a 0.0001 cM recombination fraction between
the two polymorphisms. The association between 5-HTT gene polymorphisms and blood 5-
HT levels was tested using ANOVA and Student’s t-test.
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Table 1 Transmission/disequilibrium test of two 5-HTT gene polymorphisms and autistic disorder
Allele Trios Sib pairs Total sample
T NT T NT T NT
5-HTTLPR
Short 28 19 43 36 71 55
Long 19 28 36 43 55 71
TDT χ2 = 1.73, df = 1, p < 0.19 TDT χ2 = 0.62, df = 1, p < 0.43 TDT χ2 = 2.03, df = 1, p < 0.15
5-HTT intron 2 VNTR
Stin2.9 2 2 4 2 6 4
Stin2.10 21 12 29 36 50 48
Stin2.12 13 22 36 31 49 53
TDT χ2 = 2.50, df = 2, p < 0.28 TDT χ2 = 1.30, df = 2, p < 0.52 TDT χ2 = 0.47, df = 2, p < 0.78
T = transmitted, NT = not transmitted.
Table 2 Transmission/disequilibrium test of the haplotypes of the 5-HTTLPR and intron 2 VNTR
polymorphisms of the 5-HTT gene and autistic disorder
Haplotype Trios Sib pairs Total sample
Obs Exp Obs Exp Obs Exp
Long/Stin2.9 2.00 2.07 4.08 3.12 6.10 5.21
Long/Stin2.10 23.82 21.57 62.40 66.36 86.12 87.69
Short/Stin2.10 6.17 4.27 16.98 14.91 23.07 18.97
Long/Stin2.12 17.17 23.86 47.60 48.40 64.79 72.27
Short/Stin2.12 36.82 34.22 62.92 61.20 99.91 95.85
TDT χ2 = 6.42, df = 4, p < 0.02 TDT χ2 = 1.92, df = 4, p < 0.75 TDT χ2 = 4.01, df = 4, p < 0.45
Obs = observed, Exp = expected.
Table 3 Whole blood 5-HT levels and 5-HTT gene polymorphisms in autistic patients
Genotype n Blood 5-HT
(µmol/l, mean ± SD)
5-HTTLPR
Short/short 8 0.99 ± 0.46
Short/long 27 0.95 ± 0.31
Long/long 10 1.48 ± 1.31
5-HTT intron 2 VNTR
Stin2.9/Stin2.10 3 0.89 ± 0.06
Stin2.10/Stin2.10 8 1.42 ± 1.48
Stin2.10/Stin2.12 17 1.15 ± 0.39
Stin2.12/Stin2.12 16 0.89 ± 0.35
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